



**23rd TCTAP 2018**  
**Complex PCI: Make It Simple!**



**Left Main PCI: Unmet Questions?**

**Dr Tan Huay Cheem**

MBBS, M Med(Int Med), MRCP (UK), FRCP(Edin), FAMS, FACC, FSCAI

Director, National University Heart Centre, Singapore (NUHCS)

Professor of Medicine, Yong Loo Lin School of Medicine, National University of Singapore

President, Asia Pacific Society of Interventional Cardiology



# Unanswered Questions

- Which Patients Should Undergo PCI vs CABG?
- Which Stent To Use?
- What Techniques To Employ? (One-vs Two stent)


# Unanswered Questions

- **Which Patients Should Undergo PCI vs CABG?**
- Which Stent To Use?
- What Techniques To Employ? (One-vs Two stent)

# SYNTAX: MACCE to 5 Years

■ CABG (N=897)

■ TAXUS (N=903)







Cumulative KM Event Rate  $\pm$  1.5 SE; log-rank *P* value; \*Binary rates

ITT population

Mohr FW et al Lancet 2013; 381: 629-38



# SYNTAX Left Main Subgroup: 5 Year Events



**Conclusions:** No difference in MACCE at 5 Years.  
PCI pts lower stroke but higher revascularization rate vs CABG

# EXCEL Trial: Study Design

2900 pts with Unprotected Left Main Disease

SYNTAX score  $\leq 32$

Consensus agreement of eligibility and equipoise by heart team

Yes

(N=1900)

No

(N=1000)

Enrollment  
registry

Stratified by diabetes,  
SYNTAX score and center

R

PCI (Xience EES)  
(N=950)


CABG  
(N=950)

**Primary Endpoint: CV Death, MI (CKMB >10x), Stroke at 3 Years**

GW Stone et al N Engl J Med 2016; 375: 2223-2235



# EXCEL Primary Endpoint: Death, Stroke or MI at 3 Years




No. at Risk:

	0	1	6	12	24	36
PCI	948	896	875	850	784	445
CABG	957	868	836	817	763	458

GW Stone et al N Engl J Med 2016; 375: 2223-2235

# NOBLE (Nordic-Baltic-British Left Main Revascularization) Primary Endpoint: MACCE At 5 Years

n= 1201 (SAP/UA/NSTEMI) pts randomised 1:1 to treatment with PCI or CABG



**PCI did not show non-inferiority  
and CABG was superior to PCI**

Makikallio T et al Lancet 2016; 388: 2743-2752





# NOBLE: Kaplan-Meier 5 year Estimates by Intention-To-Treat

	PCI (n=592)	CABG (n=592)	Hazard ratio (95% CI)	p value
MACCE	29% (121)	19% (81)	1.48 (1.11-1.96)	0.0066
All-cause mortality	12% (36)	9% (33)	1.07 (0.67-1.72)	0.77
Cardiac death	3% (14)	3% (15)	0.93 (0.45-1.92)	0.84
Vascular death	1% (2)	<1% (1)	1.96 (0.18-21.66)	0.55
Non-procedural myocardial infarction	7% (29)	2% (10)	2.88 (1.40-5.90)	0.0040
Revascularisation (total)	16% (71)	10% (47)	1.50 (1.04-2.17)	0.032
Revascularisation with PCI	13% (56)	10% (45)	1.23 (0.83-1.83)	0.29
Revascularisation with CABG	4% (19)	<1% (2)	9.40 (2.19-40.38)	0.0026
Target lesion revascularisation	12% (50)	8% (36)	1.38 (0.90-2.12)	0.14
Target LMCA revascularisation	10% (41)	9% (33)	1.23 (0.78-1.94)	0.37
De-novo lesion revascularisation*	6% (24)	3% (11)	2.34 (1.16-4.74)	0.018
Symptomatic graft occlusion or definite stent thrombosis	3% (9)	4% (15)	0.59 (0.26-1.36)	0.22
Possible stent thrombosis	1% (4)	0	..	..
Probable stent thrombosis	<1% (2)	0	..	..
Stroke	5% (16)	2% (7)	2.25 (0.93-5.48)	0.07

Makikallio T et al Lancet 2016; 388: 2743-2752



# What Did We Learn from EXCEL and NOBLE?

- Both NOBLE and EXCEL trials showed that PCI and CABG confer a similar survival benefit in revascularization of ULMCAD over intermediate-term follow-up
- Repeat revascularization is more likely with PCI compared to CABG, and there may be an increased risk of spontaneous MI with PCI when using non-EES DES
- Need for an experienced heart team, familiar with current best practices and techniques, in managing these patients to achieve optimal outcomes
- Longer-term follow-up data from both trials will provide insights into the durability of the results for both PCI and CABG
- The decision between PCI and CABG for ULMCAD should be based on weighing the benefits and risks of PCI versus CABG and taking patient preference into consideration

# Unanswered Questions


- Which Patients Should Undergo PCI vs CABG?
- **Which Stent To Use?**
- What Techniques To Employ? (One-vs Two stent)

# Special Stent Considerations for Left Main PCI

- Radial strength
- Large calibred vessel  
(often size mismatch with daughter vessels)
- Side branch access (for complex distal bifurcation stenting)

# Comparison of Stent Radial Force Bench Test

(Amount of radial force required to reduce the diameter of a deployed stent)




# Maximal Expansion Capacity of DES Platforms: A Critical Factor for Stent Selection in the Treatment of Left Main Bifurcations

✓ How to select a stent in Left-Main ?


Xience Prime 3.0

3.0 Xience Prime from  
LCx to LM with 4.5mm  
proximal post-dilatation



Xience Prime 3.5

3.5 (LWH) Xience Prime from  
LAD to LM with 4.5mm  
proximal post-dilatation



- ✓ In presence of a large diameter mismatch, we should look at stent model designs and expansion capacity
- ✓ Or upscale to a larger diameter (at low pressure)

Foin EuroPCR 2012

National University Health System  
Tang Enn (in School of Medicine - National University Hospital - Faculty of Dentistry)





# Post-dilatation expansion and DES model designs


Balloon Max. size		Element	Xience	Taxus	Integrity	BioMatrix	Cypher					
4.0	2.25	Very Small (2 cells) <i>max exp.: 3.0mm</i>	Medium vessel workhorse (6 crowns, 3 cells) <i>max. expansion: 4.4mm</i>	Small vessel workhorse (6 crowns, 2 cells) <i>max expansion: 3.4mm</i>	Small vessel workhorse (7 crowns, 2 cells*) <i>max expansion: 4.9mm</i>	Medium vessel workhorse (6 crowns, 2 cells) <i>max expansion: 4.6mm</i>	Medium vessel workhorse (6 crowns, 6 cells) <i>max expansion: 4.7mm</i>					
	2.50	Small vessel workhorse (8 crowns, 2 cells)										
	2.75											
5.0	3.00	<ul style="list-style-type: none"> <li>• All stents have capacity to be overexpanded well above their labelled maximal diameter</li> <li>• For most DESs, MLD &gt; 5.5mm was achieved after 6.0mm balloon post-dilatation</li> </ul>										
	3.50											
	4.00							Large vessel (10 crowns, 2 cells) <i>max expansion: 5.7mm</i>	5.6mm	Large vessel (9 crowns, 3 cells) <i>max expansion: 6.0mm</i>		5.9mm
6.0	4.50											
	5.00											

- Minimal stent LD excluding struts
- Limited to 6.0 mm balloon at 14 ATM

Foin N et al Eurointervention 2013; 8: 1315-25

# Side Branch Access

Cell size after SB dilatation: Comparison of 4 DES designs  
(3.0mm stent, dilatation across cell with 4.0mm NC Balloon at 14 ATM)



Foin et al EuroIntervention 2013; 9: 885-7




# Did Different Stents Used In EXCEL and NOBLE Matter?

- NOBLE, 11% who underwent PCI received a 1<sup>st</sup> generation DES. The 2<sup>nd</sup> generation DES biolimus-eluting stent (BES) was not introduced as the “stent of choice” until well into enrollment.
- More spontaneous MI in the PCI group (**6%**) in NOBLE, compared with **4.3%** in PCI group in EXCEL
- In NOBLE, **2%** definite stent thrombosis rate on 5-year Kaplan Meier estimates (0.8% for recipients of the BES) compared to EXCEL which had a **0.7%** rate of stent thrombosis over 3 years.
- Higher rate of spontaneous MI and revascularization drove the primary composite endpoint in favor of CABG in NOBLE.

# IDEAL Left Main: OCT Analysis

First randomized study comparing two types of DES  
in LM on apposition and coverage



Distal Main	BP-PtCr-EES (N=48)	PP-CoCr-EES (N=43)	P-Value
Mean lumen area	9.51 ± 2.05	8.85 ± 2.59	0.177
Minimal lumen area	7.37 ± 2.20	6.74 ± 2.43	0.198
Endoluminal: Mean stent area	9.87 ± 1.86	9.35 ± 2.36	0.251
Endoluminal: Mean neo-intima areas	0.72 ± 0.31	0.84 ± 0.48	0.912
Uncovered struts (%)	0.00 ± 0.00	0.02 ± 0.16	0.291
Covered >20 micron (%)	96.29 ± 4.13	97.23 ± 2.42	0.468
Malapposed struts (%)	3.07 ± 6.80	1.62 ± 2.69	0.758
Endoluminal: Mean ISA area	0.18 ± 0.39	0.11 ± 0.23	0.758

## Conclusion

- 100% coverage at 3 months for both DES types
- Very low % malapposition for both DES types

Robert-Jan van Geuns Hot Line Session EuroPCR 2017




# Unanswered Questions

- Which Group Should Undergo PCI vs CABG?
- What Stents To Use?
- **What Techniques To Employ? (One-vs Two stent)**

# SYNTAX: Left Main Distal Stenting Techniques

LM Distal PCI (211 LM lesions)





89% of provisional T-stenting lesions used only 1 stent; 9% used 2 stents

# EXCEL Trial: Planned Routine 2 Stents for LM Distal Bifurcation Disease (n=185; 34.8%)


Planned 2-stent technique	Site-assessed N=185
T, Modified T, TAP	50.8%
Culotte	23.2%
Crush/Mini-Crush	14.4%
V Stent	6.1%
Simultaneous Kissing Stent	2.8%
Other	2.8%

# DK CRUSH-III (DK Crush vs Culotte of Distal Left Main Bifurcation): 3 Year Clinical Follow Up




- Higher MACE driven mainly by increased MI (8.2% vs 3.4%,  $p = 0.037$ ) and target-vessel revascularization (18.8% vs 5.8%,  $p < 0.001$ )
- Definite ST rate 3.4% in Culotte vs 0% in the DK Crush group ( $p = 0.007$ )

# DKCRUSH V





# DK CRUSH V Primary Endpoint: Target Lesion Failure



Chen SL et al J Am Coll Cardiol 2017;70: 2605-2617





# DKCRUSH V: Primary and Secondary Endpoints

	DK crush (N=240)	Provisional (N=242)	<i>P</i> value
<b>Primary endpoint components at 30 days</b>			
- Cardiac death	0	1.7	0.046
- Target vessel MI	0.4	1.7	0.10
- TLR	0.4	0.4	1.00
<b>Primary endpoint components at 1 year</b>			
- Cardiac death	1.2	2.1	0.48
- Target vessel MI	0.4	2.9	0.03
- TLR	3.8	7.9	0.06
<b>Secondary endpoints at 1 year</b>			
- All-cause death	2.9	2.1	0.58
- Any revascularization	5.4	7.9	0.32
- Angina	4.5	9.3	0.06
<b>Stent thrombosis (def/prob)</b>			
- 30 days	0.4	2.5	0.06
- 1 year	0.4	3.3	0.02

# DKCRUSH V: Target Lesion Failure at 1-Year



## Simplex vs Complex Bifurcation Lesions



LCX-LL < 10 mm  
and/or LCX DS < 70%



Simple Lesions




LCX-LL ≥ 10 mm  
and LCX DS ≥ 70%



Complex Lesions

Plus ≥ 2 of 6 minor criteria



# Conclusions

- PCI with DES for UPLM is safe and effective in appropriately selected patients
- 2<sup>nd</sup> generation EES provides the current best data for left main PCI
- Uncertain if any specific 2-stent strategy is superior
- Discussion among cardiologists and surgeons in a ‘heart team’ of a patient’s optimal revascularisation strategy remains the best approach

14<sup>th</sup>

# AICT

ASIAN INTERVENTIONAL CARDIOVASCULAR THERAPEUTICS  
THE OFFICIAL CONGRESS OF APSIC



**7-9th September 2018**

**Hong Kong**

Convention and Exhibition Centre (HKCEC)

[www.aict-congress.com](http://www.aict-congress.com)